Background Management of tuberculosis in patients with HIV in eastern Europe is complicated by the high prevalence of multidrug-resistant tuberculosis, low rates of drug susceptibility testing, and poor access to antiretroviral therapy (ART). We report 1 year mortality estimates from a multiregional (eastern Europe, western Europe, and Latin America) prospective cohort study: the TB:HIV study.
Introduction
The high prevalence of multidrug-resistant tuberculosis in eastern Europe presents a substantial challenge to the management of the combined epidemic of tuberculosis and HIV. [1] [2] [3] The number of people with both tuberculosis and HIV is increasing rapidly and the mortality rate of these patients in this region is among the highest in the world, 2,4-7 but little published evidence from eastern Europe exists on the management of co-infected patients and risk factors for excess mortality. We have previously described the clinical aspects of the tuberculosis-HIV epidemic in eastern Europe, when the retrospective TB:HIV study was done. 4 The reasons for the high mortality rate in eastern Europe are complex and multifactorial.
The TB-HIV epidemic in this region is mainly driven by injecting drug users, a population group that needs a special multidisciplinary health-care approach to maintain retention in care and good treatment adherence. 2, [5] [6] [7] [8] Many of these patients are not engaged with health-care services despite awareness of their HIV diagnosis and are therefore not receiving antiretroviral therapy (ART), which allows immunodefi ciency to progress and severe tuberculosis disease to develop. 4 Meanwhile, management of those patients with HIV and tuberculosis who are engaged in health care seems to be suboptimal. 4, 8 Initiation of ART in this region is often delayed, even after TB is diagnosed. 4 Medical treatment of tuberculosis is inadequate, as shown by a high prevalence of drug-resistant mycobacteria and by diverse use of only partly eff ective tuberculosis drug regimens. 8, 9 Opioid substitution therapy is rarely prescribed in the region, either because it is not available or is prohibited. 8, 10 Finally, social support for injecting drug user populations in eastern Europe is very scarce (Rakhmanova AG, St Petersburg AIDS Centre, Russia, personal communication).
Supporting the theory that management of tuberculosis in patients with HIV in eastern Europe is inadequate, we previously found that most deaths were linked to untreated tuberculosis disease, and rarely to other opportunistic infections. 11 The coepidemic in eastern Europe is a public health emergency that continues to grow. 1, 2 Despite this fact, little direct documentation of its detrimental eff ects exists. We designed a prospective study of a large cohort of HIV-positive patients diagnosed with tuberculosis in countries of eastern Europe, western Europe, and Latin America. 8 The latter two regions were chosen to provide a comparison with eastern Europe and to establish a benchmark for management of tuberculosis in people living with HIV. The aim of the present report is to assess and compare 1-year mortality after tuberculosis diagnosis across regions. Additionally, we aimed to assess whether or not prognostic markers identifi ed at diagnosis of tuberculosis translated into excessive death rates.
Methods

Study design and participants
The TB:HIV prospective study was initiated in 2011 within the EuroCoord collaboration. The study is a collaboration of clinicians from 62 HIV and tuberculosis clinics in 19 countries in eastern Europe, western Europe, and Latin America. Details of the study infrastructure have been published previously. 8 Briefl y, patients were eligible for enrolment if they were HIV positive (before, or up to 3 months after a diagnosis of tuberculosis), 16 years of age or older, and diagnosed with active
Research in context
Evidence before this study Evidence about the co-epidemic of tuberculosis and HIV in eastern Europe is generally scarce with poor surveillance systems and few clinical studies. Few studies have provided data for patients co-infected with tuberculosis and HIV in this region. We searched PubMed for articles published before Dec 11, 2015 , with the terms "HIV", "tuberculosis", "Eastern Europe", "Europe", "Latin America", "drug-resistance", "MDR-TB", "XDR-TB", and "injecting drug abuse", and "outcome" in diff erent combinations. We included only studies published in English or Russian. Several cohort studies and surveillance databases had previously reported a signifi cantly reduced incidence of tuberculosis and improved mortality after implementation of antiretroviral therapy in high-income countries. The protective eff ect of antiretroviral therapy, especially in patients with severe immune suppression, has also been shown. A few studies have reported about antituberculosis drug resistance in diff erent countries in eastern Europe. Our group has previously published results from a retrospective cohort of patients co-infected with HIV and tuberculosis, in which we documented 1-year mortality of around 30% in patients with HIV and tuberculosis in eastern Europe, which was at least three times higher than in patients from western Europe and Argentina. Otherwise, we did not identify any prospective data about the management and outcomes of patients with tuberculosis and HIV co-infection in eastern Europe.
Added value of this study
To the best of our knowledge, this is the fi rst prospective international cohort study on the epidemiology and clinical aspects of patients co-infected with tuberculosis and HIV across Europe and Latin America. We provide detailed clinical data about tuberculosis drug resistance and the clinical management of patients co-infected with tuberculosis and HIV in Europe and Latin America. We have specifi cally focused on countries from eastern Europe where the tuberculosis and HIV epidemic is of particular concern because of rapidly increasing rates of co-infected patients, and where the prevalence of multidrug-resistant tuberculosis is among highest in the world. The study is the fi rst to show the suboptimum management of patients with both tuberculosis and HIV originating from eastern Europe along with very high rates of multidrug-resistant tuberculosis, resulting in alarmingly high mortality rates in the region, with the main cause of death being tuberculosis related. Mortality was especially high in patients who started antituberculosis treatment with an inadequate number of active drugs according to the drug susceptibility test result or who did not have a drug susceptibility test done. Furthermore, the study highlights concerns of low use of antiretroviral therapy in eastern Europe. Finally, the study addresses not only clinical but also public health issues related to tuberculosis-HIV co-infection, especially in eastern Europe.
Implications of all the available evidence
The fi ndings from our study draw attention to the increasing problem of the tuberculosis-HIV epidemic in eastern Europe and emphasise the urgent need for restructuring the health-care approach to patients with co-infection in this region. The results of this study emphasise the importance of integrating tuberculosis and HIV services, and of the provision of other health-care and social services to these vulnerable patients. Improvement and implementation of more accurate and rapidly available tuberculosis diagnostics and drug susceptibility tests are needed in eastern Europe to ensure timely and adequate antituberculosis treatment. Such an approach is essential to assure patients' retention in care and initiation of antiretroviral therapy when indicated. More studies are needed to address these issues further to improve the outcomes for co-infection with HIV and tuberculosis in the eastern European region.
For the EuroCoord collaboration see http://www. chip.dk tuberculosis disease between Jan 1, 2011, and Dec 31, 2013. Participating clinics had to enrol all consecutive patients with HIV and tuberculosis diagnosis within the aforementioned timeframe; each patient was then followed up for 2 years. The study was approved by the ethics committees of participating countries or clinics and written informed consent was obtained if required by local and national regulations. All patients' data were obtained from patients' medical records or via database exchange with HICDEP format.
Procedures and defi nitions
Demographic, clinical, and laboratory data, and data about patients' outcomes were collected on case report forms for both tuberculosis disease and HIV infection at the time of tuberculosis diagnosis and at 6 months, 12 months, and 24 months of follow-up (study protocol and case report forms are available online). 8 Clinical information at the time of death was collected on specifi c coding causes of death case report forms. 11, 12 These forms were assessed by two clinicians at the coordinating centre and the underlying causes of death were categorised as tuberculosis-related, or not. Data were extensively quality assured both at the coordinating centre, and through site visits with data monitoring of all deaths, multidrugresistance cases, and a random sample of 10% of the remaining participants.
Antituberculosis drugs initiated within 10 days of when the fi rst antituberculosis drug was started were considered to comprise an initial regimen, and tuberculosis treatment was categorised as RHZ-based (containing at least a rifamycin, isoniazid, and pyrazinamide), or other (panel). Initial antituberculosis treatment was further assessed according to the number of active drugs in the regimen based on results of locally performed drug susceptibility tests on a Mycobacterium tuberculosis sample taken up to 1 month before or after initiation of antituberculosis treatment (baseline drug susceptibility test). For the primary analysis, we judged all M tuberculosis isolates with some drug susceptibility test results available to be susceptible to drugs for which there was no indication of resistance (ie, if no data were available for a specifi c drug, the isolate was considered susceptible to that drug). All patients with available results for both rifamycin and isoniazid at baseline were classifi ed into three groups (panel): multidrug-resistant tuberculosis (resistance to both rifamycin and isoniazid); mono-resistance (resistance to either rifamycin or isoniazid but not multidrug resistant); and drug-susceptible tuberculosis (susceptible to rifamycin and isoniazid). A fourth category of patients comprised those with no available baseline drug susceptibility test data for rifamycin and isoniazid. Patients with mono-resistance to either isoniazid (n=34) or rifamycin (n=6) were grouped together because of the small numbers of patients.
Statistical analysis
All patients enrolled into the TB:HIV study who met inclusion criteria and who started antituberculosis treatment were included in the present analyses. All patients were stratifi ed into three geographical regions according to their country of residence: eastern Europe, western Europe, or Latin America (panel). Comparative analyses were done across regions. Baseline characteristics were compared with χ² or Kruskal-Wallis tests as appropriate.
The endpoint was defi ned as overall and tuberculosisrelated death within the fi rst 12 months after treatment initiation. Follow-up was either until death, the fi nal visit, or 12 months after baseline, whichever occurred fi rst. In the analysis of tuberculosis-related mortality, patients who died of any other causes were censored at the date of death. Unknown causes of death were judged not related to tuberculosis.
All-cause and tuberculosis-related mortality rates were analysed with Kaplan-Meier estimates for patients stratifi ed by geographical region, drug susceptibility, and the number of active drugs in the initial regimen (three or more, fewer than three, or unknown). For this analysis, western Europe and Latin America were combined because of the low number of deaths. The number of active drugs in the initial regimen was calculated retrospectively based on the results of the baseline drug susceptibility test. Risk factors for death were analysed with Cox regression analysis. Because of co-linearity, two multivariate models were tested: one adjusted for multidrug-resistant tuberculosis and the other adjusted for number of active drugs in the initial regimen. Other variables defi ned a priori were age, sex, region of residence, history of injecting drug use, type of tuberculosis diagnosis (defi nite vs not), clinical presentation of tuberculosis (disseminated vs not), presence of multidrug-resistant tuberculosis, drugs used for initial tuberculosis treatment (RHZ-based vs other), number of active antituberculosis drugs in the initial regimen, hepatitis C status, CD4 cell count, and use of ART (defi ned as a combination of at least three antiretroviral drugs from any class as a time-updated variable).
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
A total of 1406 patients were eligible for the current analyses (table 1) . In all three regions, patients who died were more likely to have lower CD4 cell counts, and in eastern and western Europe patients who died also had a lower bodyweight compared with those alive. Disseminated tuberculosis and initial antituberculosis treatment regimen with fewer than three drugs were much more common in patients who died than in those alive in eastern Europe. (0-3) in western Europe and 4% (2-8) in Latin America (p<0·0001; fi gure 1B). The 1 year probability of tuberculosis-related death was strongly aff ected by multidrug-resistant tuber culosis status and the number of active drugs in the initial treatment regimen. Tuberculosis-related mortality ranged from 10% (95% CI 6-17) in patients without multidrugresistant tuberculosis to 32% (23-43) in those with multidrug-resistant tuberculosis in eastern Europe, and from 1% (0-4) to 19% (7-49) in western Europe and Latin America combined (fi gure 2). Patients in eastern Europe who started antituberculosis treatment with three or more active drugs had a substantially lower risk of death from (table 2) ; one model included antituberculosis drug susceptibility, and the other the number of active drugs in the initial antituberculosis regimen. The probability of death was roughly three-times higher in patients with multidrugresistant tuberculosis (fi rst model) and in those whose initial antituberculosis regimen contained fewer than three active drugs (second model). Other signifi cant risk factors for death in both models were female sex, the presence of disseminated tuberculosis, lower CD4 cell count, and non-use of ART. Initiation of an RHZ-based 
Discussion
The 1-year cumulative probability of death in patients with HIV and tuberculosis disease in eastern Europe continues to be very high (29%) and substantially higher than in another middle-income region (Latin America, 11%) and a high-income region (western Europe, 5%). In more than two-thirds of those who died in eastern Europe, the cause of death was considered to be tuberculosis, and the excess mortality in this region could not be explained by regional diff erences in other clinical and demographic prognostic factors such as sex, 
Defi nite tuberculosis diagnosis 
No baseline drug susceptibility test
RHZ-based treatment
Injecting drug use CD4 cell count at time of tuberculosis diagnosis, receipt of ART, disseminated tuberculosis disease, documented multidrug-resistant tuberculosis, or choice of initial antituberculosis regimen. These results should be interpreted in the context of the documented high prevalence of multidrug-resistant tuberculosis in eastern Europe, which is among the highest in the world. 2, 13 In our study, 39% of patients had multidrug-resistant tuberculosis at the time of starting antituberculosis therapy (ie, primary multidrug-resistant tuberculosis). Worldwide, only 20% of patients with multidrug-resistant tuberculosis are receiving adequate antituberculosis treatment, 2 and treatment success rates are about 50% in Russia, and vary between 36% and 80% in the rest of the world.
2,14-16 Treatment of multidrugresistant tuberculosis needs a sophisticated multidisciplinary approach, drawing on expertise from many specialties. Favourable outcomes depend on many factors, in particular the activity of the antituberculosis treatment regimen provided, the duration of treatment, and the patients' adherence. 17 To design an adequate empirical antituberculosis regimen (ie, before the availability of drug susceptibility test results) is a diffi cult task and naturally relies on knowledge of the prevailing antituberculosis drug resistance pattern in a particular location. 18 In our study, in settings with a low prevalence of multidrug-resistant tuberculosis such as western Europe and Latin America, the initial treatment regimen included at least three active drugs in most patients, and mortality rates for patients without drug susceptibility tests (accordingly without the possibility of targeting the subsequent treatment) were similar to those in patients starting at least three active drugs (according to the subsequent drug susceptibility test results). Although the results should be interpreted cautiously, this fi nding suggests that many patients who did not have drug susceptibility tests were infected with susceptible M tuberculosis strains and standard RHZ-based treatment was effi cient. The situation is diff erent in eastern Europe where there is a high prevalence of multidrug-resistant tuberculosis. Here, the mortality in patients without drug susceptibility tests and in patients who started fewer than three active antituberculosis drugs was much higher than in those who started treatment with at least three active drugs. These data underscore the importance of constructing an initial empirical regimen of suffi ciently high activity, and of obtaining an initial drug susceptibility test in high multidrug-resistant tuberculosis settings; the latter allows subsequent individualised antituberculosis treatment guided by the drug susceptibility test results.
Although phenotypic drug susceptibility testing remains the gold standard for the detection of M tuberculosis resistance, genotypic tests signifi cantly reduce the time needed for determination of resistance, especially rifampicin resistance, and rapid genotypic tests have recently become more available and are of 10, [17] [18] [19] However, the number of drugs assessed within these tests is currently low, which is a disadvantage in the context of high multidrugresistant tuberculosis prevalence. In the provision of a tuberculosis service, ensuring availability of diagnostics and drug susceptibility testing (especially rapid testing) and access to antituberculosis drugs for treatment of multidrug-resistant tuberculosis to improve the outcome from the disease is of paramount importance, but is still not the case in many countries of eastern Europe. 10 Therefore, these key steps in the successful management of tuberculosis should be in every way promoted and actively encouraged by health-care policy makers.
We have previously documented high mortality rates in eastern Europe (nearly 30%) in a previous retrospective precursor of the TB:HIV study (done during 2004-06), which largely included the same clinics as the present study. 4 Although direct comparisons should be made with caution because of the small diff erences in participating clinics or countries, mortality rates do not seem to have improved since the retrospective study, and the prevalence of multidrug-resistant tuberculosis is higher in the present study. 4, 8 By contrast, uptake of ART in patients with HIV and tuberculosis has improved in all study regions, probably because of the accumulating evidence for the clinical benefi t of starting ART after tuberculosis diagnosis, especially in patients with pronounced immunodefi ciency. [20] [21] [22] However, patients continue to present with tuberculosis at low CD4 cell counts, and in the present study only two-thirds of the patients in eastern Europe who remained under follow-up at 12 months after tuberculosis diagnosis had started ART.
Tuberculosis and HIV inpatient and outpatient services in many eastern European countries are disintegrated, and a patient with tuberculosis and HIV often has to visit several health-care institutions to obtain treatment for both diseases ( 10 The inferior tuberculosis-related results in eastern Europe described in this report call for an improvement of tuberculosis management, including integration of HIV and tuberculosis services and involvement of other services addressing other social and health issues that these patients might face. 23, 24 Although the benefi ts of opioid substitution therapy for people who inject drugs have been documented, this service is still illegal, or is only scarcely available, in many countries in eastern Europe. 10, 25 Because of its infrequent use in the present study, the role of opioid substitution therapy could not be analysed in detail.
Importantly, eastern Europe is a very heterogeneous region and, in agreement with our previous report of pronounced variability within the region in the prevalence of multidrug-resistant tuberculosis and in the management of patients with HIV and tuberculosis co-infection, we recorded large variation in 1-year mortality across the area. However, the number of patients enrolled in the various clinics in eastern Europe did not allow for more detailed analyses of diff erences within the region. 8, 10 The main strengths of the TB:HIV study are the prospective design with inclusion of consecutive patients, the standardised data collection, and an extensive quality assurance programme. The limitations include that some patients with HIV and tuberculosis might have been missed, especially those who were severely ill with a poor prognosis because they were not able to reach health care, and that loss to follow-up in this population of patients is generally high and might also have aff ected our results, although eff orts have been invested in the study to reduce this problem as much as possible. 26 Furthermore, the HIV and tuberculosis clinics participating in the study are major university-affi liated clinics with well established infrastructure and scientifi c experience. Therefore, the situation is unlikely to completely represent the situation in the entire eastern European region, and our fi ndings might well underestimate the problems for HIV-positive patients with tuberculosis in eastern Europe. The analysis of resistance to antituberculosis drugs and the number of active drugs is based on the reported data of resistance tests being done locally. If some drug susceptibility test results were present for a given patient but missing for a drug in the patient's initial regimen, this drug was considered to be active. Therefore, the number of active drugs might be overestimated as discussed elsewhere. 8 Sensitivity analyses with more conservative assumptions, including an analysis in which we only calculated the number of active drugs for individuals with complete drug susceptibility testing data for all the drugs they received at baseline, led to consistent results (data not shown). The few patients with resistance only to either isoniazid or rifamycin were grouped together, despite an awareness of diff erent clinical consequences for these two groups of patients.
Finally, the present study was not designed to directly assess factors such as the patients' adherence to treatment and socioeconomic factors (eg, family structure, unemployment, and poverty) that might aff ect outcomes for patients and provide further explanation for the recorded regional diff erences. Data about these factors from this region are scarce and further research and epidemic surveillance are warranted.
Within the TB:HIV study, detailed analyses are in progress addressing management following the tuberculosis diagnosis and include detailed analyses of antituberculosis treatment patterns for patients with fully susceptible tuberculosis and those with multidrugresistant disease in relation to drug susceptibility test results obtained during the course of antituberculosis treatment. Additionally, the role of the prevailing resistance patterns in relation to the choice of proper
